Company: MDCXW
Filing Date: 2025-11-17
Form Type: 424B3
Source: 0001062993-25-016875
Chunk: 15

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-17
Form: 424B3
Chunk 15
---
 following development milestones of the IPR&D:

| Phases                                                                          | Contingent Consideration agreed for Antev shares acquired through issue of shares | Contingent Consideration agreed for Antev shares acquired by cash payment |
| (i) Advanced Prostate Cancer - Phase 2 success or registration                  | $2.00 per common share issued                                                     | $1.47 per Antev share (pro rata interest in $5,333,200)                   |
| (ii) Acute Urinary Retention (AUR) Prevention - Phase 2 success or registration | $7.50 per common share issued                                                     | $5.52 per Antev share (pro rata interest in $19,999,500)                  |
| (iii) FDA NDA approval - Hormone therapy for prostate cancer                    | Up to $20,000,000 (subject to pro rata reduction)                                 | $5.52 per Antev share (pro rata interest in $20,000,000)                  |
| (iv) FDA NDA approval - AUR prevention                                          | Up to $20,000,000 (subject to pro rata reduction)                                 | $5.52 per Antev share (pro rata interest in $20,000,000)                  |

Per the terms of the acquisition, the common shares issued by the Company at Closing are subject to a staggered lock-up schedule. Specifically, 15% of the shares will be released at 30, 60, 90, 120, 150, and 180 days following the effectiveness of the Initial Registration Statement by the SEC, with the remaining 10% released on day 210. Additionally, these shares are subject to a six-month statutory hold under the U.S. Securities Act of 1933. A Registration Statement on Form S-1 has been filed with the SEC to register the shares for resale, which, once declared effective, will remove the six-month hold. 18 The Company accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified IPR&D, thus satisfying the requirements of the screen test in accordance with the criteria under ASC 805-10-55-5C. As the common shares issued by the Company are subject to lock-up restrictions, a discount of 21.4394% was applied to the quoted closing price of the Company's shares ($1.94) to determine the fair value of the Company